Pulling SEC filings + quote and writing the call…

TransMedics Group, Inc.
Next earnings Jul 28, 2026 · consensus $0.57 EPS, $188M rev
Last earnings -2.2% on 2026-05-05
Revenue grew 37.1% YoY.
Quality fundamentals and an attractive price line up (~138% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0001756262, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 12:48:20 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
TransMedics Group, Inc. shows $605M in FY2025 revenue (+37.1% YoY), a 31.4% net margin, and 40.2% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $30.3M | $93.5M | $242M | $442M | $605M |
| Gross profit | $21.2M | $65.3M | $154M | $262M | $363M |
| Operating income | -$39.4M | -$31.4M | -$28.7M | $37.5M | $109M |
| Net income | -$44.2M | -$36.2M | -$25.0M | $35.5M | $190M |
| Diluted EPS | -$1.60 | -$1.23 | -$0.77 | $1.01 | $4.87 |
| Net margin | -146.1% | -38.8% | -10.4% | 8.0% | 31.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1071 tracked peers · median
Last 90 days: 0 open-market buys · 1 sale
| 2026-06-15 | Gunderson Thomas J. Director | Exercise | 19.3K @ $2.21 | $42.6K |
| 2026-06-15 | Gunderson Thomas J. Director | Sell | 9.62K @ $75.06 | $722K |
| 2026-05-20 | Lovell Stephanie Director | Award | 2.92K | |
| 2026-05-20 | Weill David Director | Award | 2.92K | |
| 2026-05-20 | RAINES MERILEE Director | Award | 2.92K | |
| 2026-05-20 | Gunderson Thomas J. Director | Award | 2.92K | |
| 2026-05-20 | Basile Edward M Director | Award | 2.92K | |
| 2026-05-20 | TOBIN JAMES R Director | Award | 2.92K | |
| 2026-05-20 | Kania Edwin Director | Award | 2.92K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.